Safety and Preliminary Efficacy of VG801 in Patients With ABCA4 Mutation-associated Retinal Dystrophy (Stargardt Disease)

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 23, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions

Retinal Dystrophy Due to Biallelic ABCA4 MutationsStargardt Disease 1

Interventions

DRUG

VG801

Administered as specified in the single treatment arm. Study Cohort: Low dose, medium dose and high dose cohort

Trial Locations (1)

RECRUITING

Shanghai General Hospital, Shanghai

All Listed Sponsors

lead

VeonGen Therapeutics GmbH

INDUSTRY